Flora Peyvandi / X
Jun 25, 2025, 15:23
Is the Glanzmann Era Finally Over? Flora Peyvandi on Latest Bispecific Antibodies: ISTH 2025
Flora Peyvandi, Professor of Internal Medicine at the University of Milan and former President of ISTH, shared a post on X:
”How to solve the problem of patients with Glanzmann using a novel bispecific abs – ISTH2025”
So, has the Glanzmann era truly ended—or is it just taking a coffee break before staging a comeback?
Sutacimig, a novel bispecific antibody with dual binding of FVIIa and TLT-1, seems to actually resolve the issues with clot formation in Glanzmann!
More of the latest ISTH2025 news to be posted on Hemostasis Today.
-
Jul 8, 2026, 19:30Ahmed Mostafa: Why Antibodies Cause Organ Rejection
-
Jul 8, 2026, 19:28Erika Bocanegra: Witnessing 25 Years of Progress in Bleeding Disorders Care
-
Jul 8, 2026, 19:27Ahmadou Ouedraogo: Do You Know Your Blood Type?
-
Jul 8, 2026, 19:26Javed Anees: An Evidence-Based Clinical Guide to ESA Therapy
-
Jul 8, 2026, 19:25Paul Breillat: Nature Reviews Rheumatology Highlights Our VEXAS Syndrome Research
-
Jul 8, 2026, 19:25Luca Saba: Why Does the Same Patient Have Different Plaque in Different Arteries?
-
Jul 8, 2026, 19:25Luisa Weiss: Understanding the Molecular Differences Between Acute and Chronic Coronary Syndromes.
-
Jul 8, 2026, 19:11J. Meireles-Brandao: Role of Modifiable Cardiovascular Risk Factors in Dementia Development
-
Jul 8, 2026, 16:58Emmanuel J Favaloro։ Acquired von Willebrand Syndrome: Key Concepts for Clinical Practice